Discover
HALO
Halozyme Therapeutics, Inc.
102.54
1 x 102.40
1 x 102.55
bid
ask
-
0.08
0.08%
12:37 PM
timesize
| Ytd | 52.36% | |
| 1y | 63.05% |
102.22
day range
104.78
61.63
52 week range
103.12
| Open | 102.85 | Prev Close | 102.62 | Low | 102.22 | High | 104.78 | Mkt Cap | 12.16B |
| Vol | 1.04M | Avg Vol | 2.03M | EPS | 5.36 | P/E | 19.12 | Forward P/E | 9.92 |
| Beta | 0.85 | Short Ratio | 6.68 | Inst. Own | 114.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 76.90 | 200-d Avg | 70.56 | 1yr Est | 97.33 |
| Income Statement | |||
| Total Revenue | 481.00M | ||
| Revenues (USD) | 481.00M | ||
| Cost of Revenue | 79.17M | ||
| Gross Profit | 401.83M | ||
| Operating Expenses | 114.17M | ||
| Research and Development Expense | 27.66M | ||
| Selling, General and Administrative Expense | 57.00M | ||
| Operating Income | 287.65M | ||
| Interest Expense | 5.59M | ||
| Income Tax Expense | 54.99M | ||
| Net Income | 229.91M | ||
| Net Income Common Stock | 229.91M | ||
| Net Income Common Stock (USD) | 229.91M | ||
| Consolidated Income | 229.91M | ||
| Earnings per Basic Share | 1.96 | ||
| Earnings per Basic Share (USD) | 1.96 | ||
| Earnings per Diluted Share | 1.90 | ||
| Earning Before Interest & Taxes (EBIT) | 290.49M | ||
| Earning Before Interest & Taxes (USD) | 290.49M | ||
| Weighted Average Shares | 117.27M | ||
| Weighted Average Shares Diluted | 121.22M | ||
| Balance Sheet | |||
| Cash and Equivalents | 163.99M | ||
| Cash and Equivalents (USD) | 163.99M | ||
| Investments | 67.86M | ||
| Investments Current | 67.86M | ||
| Trade and Non-Trade Receivables | 455.83M | ||
| Current Assets | 933.02M | ||
| Property, Plant & Equipment Net | 84.27M | ||
| Total Assets | 2.58B | ||
| Debt Current | 208.97M | ||
| Total Debt | 2.15B | ||
| Current Liabilities | 344.44M | ||
| Debt Non-Current | 1.94B | ||
| Total Liabilities | 2.43B | ||
| Accumulated Retained Earnings (Deficit) | 151.26M | ||
| Accumulated Other Comprehensive Income | -7.83M | ||
| Shareholders Equity | 143.54M | ||
| Shareholders Equity (USD) | 143.54M | ||
| Assets Non-Current | 1.64B | ||
| Total Debt (USD) | 2.15B | ||
| Goodwill and Intangible Assets | 1.50B | ||
| Inventory | 137.14M | ||
| Liabilities Non-Current | 2.09B | ||
| Trade and Non-Trade Payables | 23.61M | ||
| Tax Liabilities | 49.06M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 33.97M | ||
| Net Cash Flow from Financing | -326.25M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -148.02M | ||
| Capital Expenditure | -4.17M | ||
| Issuance (Purchase) of Equity Shares | -327.86M | ||
| Net Cash Flow from Investing | -62.66M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -58.49M | ||
| Net Cash Flow from Operations | 240.89M | ||
| Share Based Compensation | 17.70M | ||